Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Kitakyusyu, Japan.
Department of Information Science, Iwate Medical University, Morioka, Japan.
J Obstet Gynaecol Res. 2022 Jul;48(7):1570-1579. doi: 10.1111/jog.15284. Epub 2022 May 27.
To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2019 and the Annual Treatment Report for 2014, on the outcomes of patients who started treatment in 2014.
The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2019 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2014 was analyzed by using the Kaplan-Meier, log-rank, and Wilcoxson tests.
Treatment was initiated in 2019 for 7983 patients with cervical cancer, 12 631 with endometrial cancer, 7737 with ovarian, tubal, and peritoneal cancer, 2222 with ovarian borderline tumors, and with the others (251 vulvar cancer, 148 vaginal cancer, 476 uterine sarcoma, 43 uterine adenosarcoma, 175 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients with cervical cancer were 92.5%, 76.8%, 58.6%, and 29.5% for stages I, II, III, and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 94.5%, 87.3%, 70.2%, and 26.5% for stages I, II, III, and IV, respectively. The 5-year survival rates for the patients with ovarian cancer (surface epithelial-stromal tumors) were 90.72%, 80.4%, 53.4%, and 31.6% for stages I, II, III, and IV, respectively.
The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.
提供包括日本妇科恶性肿瘤趋势的信息，现呈现 2019 年年度患者报告和 2014 年年度治疗报告，内容为 2014 年开始治疗的患者的结果。
日本妇产科协会维持着一个年度肿瘤登记处，收集来自各参与机构的妇科恶性肿瘤信息。回顾性分析 2019 年开始治疗的妇科恶性肿瘤患者的数据。使用 Kaplan-Meier、log-rank 和 Wilcoxson 检验分析 2014 年开始治疗的宫颈癌、子宫内膜癌和卵巢癌患者的生存情况。
2019 年开始治疗的宫颈癌患者 7983 例，子宫内膜癌患者 12631 例，卵巢、输卵管和腹膜癌患者 7737 例，卵巢交界性肿瘤患者 2222 例，其他患者（外阴癌 251 例、阴道癌 148 例、子宫肉瘤 476 例、子宫腺肉瘤 43 例、滋养细胞疾病 175 例）。这些临床病理信息总结为年度患者报告。宫颈癌患者的 5 年生存率分别为 I 期、II 期、III 期和 IV 期的 92.5%、76.8%、58.6%和 29.5%。子宫内膜癌患者的 5 年生存率分别为 I 期、II 期、III 期和 IV 期的 94.5%、87.3%、70.2%和 26.5%。卵巢癌（表面上皮-间质肿瘤）患者的 5 年生存率分别为 I 期、II 期、III 期和 IV 期的 90.72%、80.4%、53.4%和 31.6%。
年度肿瘤报告是一项重要的调查，提供了日本妇科恶性肿瘤趋势的知识。
